Zevra Therapeutics Shares Sink After Receiving Regulatory Blow

Dow Jones

07/24

Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder.

The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date.

Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol.

Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request.

"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe," Chief Executive Neil McFarlane said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 24, 2026 09:10 ET (13:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2653708790"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653708790\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653708790?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653708790","market":"hk","top_or_hot":-1,"title":"Zevra Therapeutics Shares Sink After Receiving Regulatory Blow","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a> tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n</p>\n<p>\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n</p>\n<p>\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n</p>\n<p>\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n</p>\n<p>\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2026 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zevra Therapeutics Shares Sink After Receiving Regulatory Blow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZevra Therapeutics Shares Sink After Receiving Regulatory Blow\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-24 21:10</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ZVRA\">Zevra Therapeutics</a> tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n</p>\n<p>\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n</p>\n<p>\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n</p>\n<p>\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n</p>\n<p>\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 24, 2026 09:10 ET (13:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653708790","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653708790","pubTimestamp":1784898600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder.The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date.Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol.Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request.\"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said.Write to Connor Hart at connor.hart@wsj.com Dow Jones Newswires","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ZVRA":"Zevra Therapeutics"},"translate_title":"Zevra Therapeutics 股价在受到监管打击后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1.5},"content_text":"Shares of Zevra Therapeutics tumbled after a European regulator adopted a negative opinion of the company's treatment for Niemann-Pick disease type C, a rare and life-threatening neurodegenerative disorder. \n\n\n  The stock fell 27% to $9.20 in premarket trading Friday. Through Thursday's close, shares are up roughly 50% year to date. \n\n\n  Zevra said before the bell that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion regarding the marketing authorization application for the treatment, called arimoclomol. \n\n\n  Under European regulatory procedures, Zevra said it plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request. \n\n\n  \"While the review did not result in the outcome we had hoped for, we are committed to investigating appropriate pathways to bring arimoclomol to patients in Europe,\" Chief Executive Neil McFarlane said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 24, 2026 09:10 ET (13:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}